









## UPDATE OF THE EARLY DEMAND MAP FOR THE PUBLIC INNOVATION PURCHASE OF THE MedeA PROJECT (PUBLISHED IN APRIL 2019).

NOTE: Corresponds to Challenge I on the Initial Early Demand Map (April 2019).

CHALLENGE I: DEVELOPMENT OF PERSONALISED PRESCRIPTION SYSTEM - CLINICAL DECISION SUPPORT SYSTEM		[PoPS.0-PoPS.1]
NEED	DESCRIPTION	PROCEDURE TO FOLLOW
It is required to generate a tool that supports decision-making for the selection of the most appropriate drug/s and their dose/s in the context of pharmacological treatment and clinical conditions of the patient, so that it provides:  • Optimization in the choice of drug/s and appropriate doses, based on pharmacogenetic biomarkers and other determinants of variability in response, to prevent adverse drug reactions (ADRs) and therapeutic failures and ultimately reduce health service costs. Some of the necessary information is in the Electronic Health Record (EHR) and some will be new generation (genetic biomarkers, interactions).  • The system should be integrable/connectable with the EHR of the Extremadura Health Service (SES), so that it allows the incorporation of various databases containing genetic and pharmacological information, as well as patient-related information; the interrelated analysis of this information; and the generation of a response within the framework of a prescription support system (alarms, additional information, recommendations, etc.) [PoPS.0].	Oriented Drug Prescription ("Personalized Oriented Drug Prescription System: PoPS 0), with a Clinical Data Visualization	Innovative Public Procurement / Innovation Partnership

Budget available Challenge I: 1,343,118 €.

Maximum budget to be awarded per company in Phase I (VAT included): 895,411.76 €.